Literature DB >> 16186486

Elucidation of IgH intronic enhancer functions via germ-line deletion.

Thomas Perlot1, Frederick W Alt, Craig H Bassing, Heikyung Suh, Eric Pinaud.   

Abstract

Studies of chimeric mice demonstrated that the core Ig heavy chain (IgH) intronic enhancer (iEmu) functions in V(D)J and class switch recombination at the IgH locus. To more fully evaluate the role of this element in these and other processes, we generated mice homozygous for germ-line mutations in which the core sequences of iEmu (cEmu) were either deleted (cEmu(Delta/Delta) mice) or replaced with a pgk-Neo(R) cassette (cEmu(N/N) mice). The cEmu(Delta/Delta) mice had reduced B cell numbers, in association with impaired D to J(H) and V(H) to DJ(H) rearrangement, whereas cEmu(N/N) mice had a complete block in IgH V(D)J(H) recombination, confirming that additional cis elements cooperate with iEmu to enforce D to J(H) recombination. In addition, developing cEmu(Delta/Delta) and cEmu(N/N) B lineage cells had correspondingly decreased levels of germ-line transcripts from the J(H) region of the IgH locus (mu0 and Imu transcripts); although both had normal levels of germ-line V(H) transcripts, suggesting that cEmu may influence IgH locus V(D)J recombination by influencing accessibility of J(H) proximal regions of the locus. Consistent with chimera studies, peripheral cEmu(Delta/Delta) B cells had normal surface Ig and relatively normal class switch recombination. However, cEmu(Delta/Delta) B cells also had relatively normal somatic hypermutation of their IgH variable region genes, showing unexpectedly that the cEmu is not required for this process. The availability of mice with the iEmu mutation in their germ line will facilitate future studies to elucidate the roles of iEmu in V(H)(D)J(H) recombination in the context of IgH chromatin structure and germ-line transcription.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186486      PMCID: PMC1242331          DOI: 10.1073/pnas.0507090102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  An expressed neo(r) cassette provides required functions of the 1gamma2b exon for class switching.

Authors:  K J Seidl; A Bottaro; A Vo; J Zhang; L Davidson; F W Alt
Journal:  Int Immunol       Date:  1998-11       Impact factor: 4.823

2.  Deletion of the IgH intronic enhancer and associated matrix-attachment regions decreases, but does not abolish, class switching at the mu locus.

Authors:  A Bottaro; F Young; J Chen; M Serwe; F Sablitzky; F W Alt
Journal:  Int Immunol       Date:  1998-06       Impact factor: 4.823

3.  Reevaluation of 3'Ekappa function in stage- and lineage-specific rearrangement and somatic hypermutation.

Authors:  N van der Stoep; J R Gorman; F W Alt
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

4.  The 5' hypermutation boundary of kappa chains is independent of local and neighbouring sequences and related to the distance from the initiation of transcription.

Authors:  C Rada; J Yélamos; W Dean; C Milstein
Journal:  Eur J Immunol       Date:  1997-12       Impact factor: 5.532

5.  Deletion of the Ig kappa light chain intronic enhancer/matrix attachment region impairs but does not abolish V kappa J kappa rearrangement.

Authors:  Y Xu; L Davidson; F W Alt; D Baltimore
Journal:  Immunity       Date:  1996-04       Impact factor: 31.745

6.  Somatic hypermutation of immunoglobulin genes is linked to transcription initiation.

Authors:  A Peters; U Storb
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

7.  The Ig(kappa) enhancer influences the ratio of Ig(kappa) versus Ig(lambda) B lymphocytes.

Authors:  J R Gorman; N van der Stoep; R Monroe; M Cogne; L Davidson; F W Alt
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

8.  Rapid methods for the analysis of immunoglobulin gene hypermutation: application to transgenic and gene targeted mice.

Authors:  C J Jolly; N Klix; M S Neuberger
Journal:  Nucleic Acids Res       Date:  1997-05-15       Impact factor: 16.971

9.  The transcriptional promoter regulates hypermutation of the antibody heavy chain locus.

Authors:  K Tumas-Brundage; T Manser
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

10.  Class switching in B cells lacking 3' immunoglobulin heavy chain enhancers.

Authors:  J P Manis; N van der Stoep; M Tian; R Ferrini; L Davidson; A Bottaro; F W Alt
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

View more
  80 in total

1.  Enhancers located in heavy chain regulatory region (hs3a, hs1,2, hs3b, and hs4) are dispensable for diversity of VDJ recombination.

Authors:  Pauline Rouaud; Christelle Vincent-Fabert; Remi Fiancette; Michel Cogné; Eric Pinaud; Yves Denizot
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Monoallelic gene expression in mammals.

Authors:  Irina S Zakharova; Alexander I Shevchenko; Suren M Zakian
Journal:  Chromosoma       Date:  2009-02-26       Impact factor: 4.316

3.  JH6 downstream intronic sequence is dispensable for RNA polymerase II accumulation and somatic hypermutation of the variable gene in Ramos cells.

Authors:  Diana P Castiblanco; Darrell D Norton; Robert W Maul; Patricia J Gearhart
Journal:  Mol Immunol       Date:  2018-04-04       Impact factor: 4.407

4.  The mouse immunoglobulin heavy chain V-D intergenic sequence contains insulators that may regulate ordered V(D)J recombination.

Authors:  Karen Featherstone; Andrew L Wood; Adam J Bowen; Anne E Corcoran
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

5.  Requirement for enhancer specificity in immunoglobulin heavy chain locus regulation.

Authors:  Igor I Kuzin; Ludmila Bagaeva; Faith M Young; Andrea Bottaro
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

6.  Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties.

Authors:  Lynn E Macdonald; Karoline A Meagher; Matthew C Franklin; Natasha Levenkova; Johanna Hansen; Ashok T Badithe; Maggie Zhong; Pamela Krueger; Ashique Rafique; Naxin Tu; James Shevchuk; Saurabh Wadhwa; George Ehrlich; Joannie Bautista; Craig Grant; Lakeisha Esau; William T Poueymirou; Wojtek Auerbach; Lori Morton; Robert Babb; Gang Chen; Tammy Huang; Douglas MacDonald; Kenneth Graham; Cagan Gurer; Vera A Voronina; John R McWhirter; Chunguang Guo; George D Yancopoulos; Andrew J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

7.  CCCTC-binding factor (CTCF) and cohesin influence the genomic architecture of the Igh locus and antisense transcription in pro-B cells.

Authors:  Stephanie C Degner; Jiyoti Verma-Gaur; Timothy P Wong; Claudia Bossen; G Michael Iverson; Ali Torkamani; Christian Vettermann; Yin C Lin; Zhongliang Ju; Danae Schulz; Caroline S Murre; Barbara K Birshtein; Nicholas J Schork; Mark S Schlissel; Roy Riblet; Cornelis Murre; Ann J Feeney
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

8.  S-S synapsis during class switch recombination is promoted by distantly located transcriptional elements and activation-induced deaminase.

Authors:  Robert Wuerffel; Lili Wang; Fernando Grigera; John Manis; Erik Selsing; Thomas Perlot; Frederick W Alt; Michel Cogne; Eric Pinaud; Amy L Kenter
Journal:  Immunity       Date:  2007-11-01       Impact factor: 31.745

9.  Transcription of a productively rearranged Ig VDJC alpha does not require the presence of HS4 in the IgH 3' regulatory region.

Authors:  Buyi Zhang; Adrienne Alaie-Petrillo; Maria Kon; Fubin Li; Laurel A Eckhardt
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

10.  A 220-nucleotide deletion of the intronic enhancer reveals an epigenetic hierarchy in immunoglobulin heavy chain locus activation.

Authors:  Tirtha Chakraborty; Thomas Perlot; Ramesh Subrahmanyam; Anant Jani; Peter H Goff; Yu Zhang; Irina Ivanova; Frederick W Alt; Ranjan Sen
Journal:  J Exp Med       Date:  2009-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.